PIMECROLIMUS APPLICATION IN TREATMENT FOR ATOPIC DERMATITIS DURING LOCALIZATION OF THE SKIN RASH IN AREAS WITH THIN AND SENSITIVE SKIN
Abstract
Key words: atopic dermatitis, children, adults, therapy, pimecrolimus.
About the Authors
O.V. TrusovaRussian Federation
D.S. Korostovtsev
Russian Federation
References
1. Ellis C., Luger T. II Международная согласительная конференция по атопическому дерматиту (ICCAD II). Аллергология. 2003; 4: 49–59.
2. Макарова И.В. Диетотерапия и комплексный подход к наружному лечению при атопическом дерматите у детей. СПб.: МедМассМедиа. 2005. 76 с.
3. Hoeger P.H., Ott H. Противовоспалительная терапия атопической экземы у детей – традиционные стратегии и новые терапевтические возможности. Аллергология. 2004; 2: 39–47.
4. Breuer K., Braeutigam M., Kapp A., Werfel T. Influence of pimecrolimus cream 1 % on different morphological signs of eczema in infants with atopic dermatitis. Dermatology. 2004; 209: 314–320.
5. Zuberbier T., Orlow S.J., Paller A.S. et al. Patient perspectives on the management of atopic dermatitis. J. Allergy Clin. Immunol. 2006; 118: 226–232.
6. Pariser D., Paller A., Langley R., Paul C. Efficacy and local tolerability of pimecrolimus cream 1 % in the treatment of atopic dermatitis in the face/neck region of pediatric subjects. J. Invest. Dermatol. 2002; 119: 348 (Abstr. 845).
7. Eichenfield L.F., Lucky A.W., Boguniewicz M. et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1 % in the treatment of mild and moderate atopic dermatitis in children and adolescents. J. Am. Acad. Dermatol. 2002; 46: 495–504.
8. Ho V.C., Gupta A., Kaufman R. et al. Safety and efficacy of nonsteroid pimecrolimus cream 1 % in the treatment of atopic dermatitis in infants. J. Pediatrics. 2003; 142: 155–162.
9. Simon D., Lubbe J., Wuthrich B. et al. Benefits from the use of a pimecrolimus-based treatment in the management of atopic dermatitis in clinical practice. Dermatology. 2006; 213: 313–318.
10. Трусова О.В., Бальцерович Н.Б., Жиглинская О.В. и др. Применение крема Элидел в качестве основного противовоспалительного топического препарата у детей первого года жизни с персистирующим течением атопического дерматита легкой и средней степени тяжести. Аллергология. 2006; 1: 15–20.
11. Weise-Riccardi S., Ortonne J.-P., Calvieri S., et al. Randomized vehicle-controlled trial of pimecrolimus 1 % cream in adults with head and neck atopic dermatitis intolerant of, or dependent on, topical corticosteroid. J. Invest. Dermatol. 2006; 126: 46.
12. Hultsch T., Kapp A., Spergel J. Immunomodulation and safety of topical calcineurin inhibitors. Dermatology. 2005; 211: 174–187.
13. Paul C., Cork M., Rossi A.B. et al. Safety and tolerability of 1 % pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years. Pediatrics. 2006; 117: 118.
14. Gottlieb A.B., Griffiths C.E.M., Ho V.C. et al. Efficacy and tolerability of oral pimecrolimus in the treatment of moderate to severe chronic plaque-type psoriasis: a double-blind, multicentre, randomized, dose-finding trial. Br. J. Dermatol. 2005; 152: 1219–1227.
15. Van Leent E.J.M., Ebelin M.-E., Burtin P. et al. Low systemic exposure after repeated topical application of pimecrolimus (Elidel®, SDZ ASM 981) in patients with atopic dermatitis. Dermatology. 2002; 204: 63–68.
16. Thaçi D., Steinmeyer K., Ebelin M.-E. et al. Occlusive treatment of chronic hand dermatitis with pimecrolimus cream 1 % results in low systemic exposure, is well tolerated, safe, and effective. An open study. Dermatology. 2003; 207: 37–42.
17. Graham-Brown R.A.C., Grassberger M. Pimecrolimus: a review of pre-clinical and clinical data. Int. J. Clin. Pract. 2003; 57: 319–327.
18. Harper J., Green A., Scott G. et al. First experience of topical SDZ ASM 981 in children with atopic dermatitis. Br. J. Dermatol. 2004; 144: 781–787.
19. Allen B.R., Lakhanpaul M., Morris A. et al. Systemic exposure, tolerability, and efficacy of pimecrolimus cream 1 % in atopic dermatitis patients. Arch. Dis. Child. 2003; 88: 969–973.
20. Lakhanpaul M., Davies T., Allen B. et al. Pimecrolimus (SDZ ASM 981) cream 1 %: minimal systemic absorption in infants with atopic dermatitis during long term treatment (abstract). Ann. Dermatol. Venereol. 2002; 129 (Suppl.1):415.
21. Meurer M., Fölster-Holst R., Wozel G. et al. Pimecrolimus cream in the long-term management of atopic dermatitis in adults: a six month study. Dermatology. 2002; 205: 271–277.
22. Meurer M., Fartasch M., Albrecht G. et al. Long term efficacy and safety of pimecrolimus cream 1 % in adults with moderate atopic dermatitis. Dermatology. 2004; 208: 365–372.
23. Kapp A., Papp K., Bingham A. et al. Flare reduction in eczema with Elidel (infants) multicentre investigator study group: long-term management of atopic dermatitis in infants with pimecrolimus, a nonsteroid anti-inflammatory drug. J. Allergy Clin. Immunol. 2002; 110: 277–284.
24. Papp K., Werfel T., Fölster–Holst R. et al. Long-term control of atopic dermatitis with pimecrolimus cream 1 % in infants and young children: a two-year study. J. Am. Acad. Dermatol. 2005; 52: 240–246.
Review
For citations:
Trusova O., Korostovtsev D. PIMECROLIMUS APPLICATION IN TREATMENT FOR ATOPIC DERMATITIS DURING LOCALIZATION OF THE SKIN RASH IN AREAS WITH THIN AND SENSITIVE SKIN. Current Pediatrics. 2007;6(4):54-58.
Email this article 
